Credit Limit Enhancement Deacon at a Pharmaceutical Major
|
|
ICMR HOME | Case Studies Collection
Case Details:
Case Code : FINC088
Case Length : 9 pages
Period :
Pub. Date : 2013
Teaching Note : Available
Organization :Remedy Laboratories Limited
Industry : Pharmaceutical
Countries : India
To download Credit Limit Enhancement Deacon at a Pharmaceutical Major case study (Case Code:
FINC088) click on the button below, and select the case from the list of available cases:
OR
Price:
For delivery in electronic format: Rs. 300;
For delivery through courier (within India): Rs. 300 + Rs. 25 for Shipping &
Handling Charges
» Finance Case
Studies
» Short Case Studies
» View Detailed Pricing Info
» How To Order This Case
» Business Case Studies
» Area Specific Case Studies
» Industry Wise Case Studies
» Company Wise Case Studies
Please note:
This case study was compiled from published sources, and is intended to be used as a basis for class discussion. It is not intended to illustrate either effective or ineffective handling of a management situation. Nor is it a primary information source.
Chat with us
Please leave your feedback
|
|
<< Previous
|
The finance manager at Remedy Laboratories Limited (RLL) had to take a decision on whether to increase the credit limit to RLL’s major distributor in Africa, Surimex Pharmaceutical (SP), which distributed around 64% of its products in that part of the world. On the one hand, it was under pressure to increase revenue and market presence in Africa, which was not possible without SP; on the other, it realized that there was a need to do a proper credit evaluation and assessment in order to ensure there were no defaults.
|
|
Remedy Laboratories Limited: Overview
RLL was an international pharmaceutical company which had a presence in over 150 countries. It provided high quality and affordable medicines. RLL had a presence both in the developed and underdeveloped markets even though most of its revenue came from the developed markets - the U.S. and Europe. RLL bet big and focused on one of the world’s fastest growing pharmaceutical markets - the African market - and just like other global companies it put most of its efforts and resources into the African continent.
RLL was an innovation driven, science focused Generics Company. It built its branded generics business worldwide, leveraging on its strong presence in the growing emerging markets and created niche and exclusive opportunities. RLL was among the top global generics companies with sales in over 150 countries and a ground presence in 40 countries. It had global teams with expertise in multiple markets and 14,000 employees of over 50 nationalities. The USA was the largest generic market worldwide and was amongst the most important markets for RLL. Also, the company had 9 brands in the Top 100 Indian medicines list...
Excerpts
- Next Page>>
|
|
